Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GSK GSK	$36.28 -0.5%	$38.98	$31.72 ▼ $44.67	$74.67B	0.5	5.09 million shs	6.13 million shs
MRK Merck & Co., Inc.	$79.97 -1.9%	$79.37	$73.31 ▼ $128.73	$204.70B	0.39	13.48 million shs	11.65 million shs
SMMT Summit Therapeutics	$26.20 -5.2%	$22.82	$8.71 ▼ $36.91	$20.52B	-1.01	3.76 million shs	3.00 million shs
TAK Takeda Pharmaceutical	$14.42 -2.2%	$14.83	$12.80 ▼ $15.53	$46.90B	0.23	2.03 million shs	3.64 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GSK GSK	-0.59%	-5.25%	-6.15%	+1.02%	-8.91%
MRK Merck & Co., Inc.	-1.98%	-4.06%	+0.89%	+2.61%	-36.47%
SMMT Summit Therapeutics	-5.18%	+4.80%	+29.96%	+6.46%	+181.42%
TAK Takeda Pharmaceutical	-2.15%	-1.70%	-3.25%	-1.80%	+5.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GSK GSK	1.9048 of 5 stars	1.1	3.0	2.5	0.0	2.4	0.0	2.5
MRK Merck & Co., Inc.	4.9955 of 5 stars	3.2	4.0	5.0	4.2	3.5	2.5	3.8
SMMT Summit Therapeutics	3.0858 of 5 stars	4.4	3.0	0.0	0.0	2.1	1.7	0.0
TAK Takeda Pharmaceutical	2.0056 of 5 stars	0.0	5.0	2.5	0.0	2.7	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GSK GSK	2.11	Hold	$37.38	3.02% Upside
MRK Merck & Co., Inc.	2.43	Hold	$108.69	35.91% Upside
SMMT Summit Therapeutics	2.79	Moderate Buy	$34.67	32.32% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest SMMT, MRK, GSK, and TAK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	MRK Merck & Co., Inc.	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$99.00 ➝ $98.00
7/1/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
7/1/2025	SMMT Summit Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/11/2025	SMMT Summit Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
6/11/2025	SMMT Summit Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$12.00
6/3/2025	GSK GSK	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
6/2/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00
5/20/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
5/14/2025	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$115.00 ➝ $84.00
5/8/2025	SMMT Summit Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/2/2025	SMMT Summit Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $41.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GSK GSK	$31.53B	2.36	$5.55 per share	6.54	$8.07 per share	4.50
MRK Merck & Co., Inc.	$63.92B	3.14	$9.29 per share	8.61	$18.33 per share	4.36
SMMT Summit Therapeutics	$700K	27,797.08	N/A	N/A	$0.53 per share	49.43
TAK Takeda Pharmaceutical	$30.09B	1.53	$3.11 per share	4.64	$14.39 per share	1.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GSK GSK	$3.29B	$1.94	18.70	7.80	1.48	9.89%	48.82%	11.15%	7/30/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	11.64	8.08	0.85	27.27%	43.23%	17.11%	7/29/2025 (Estimated)
SMMT Summit Therapeutics	-$221.32M	-$0.34	N/A	N/A	N/A	N/A	-62.87%	-51.61%	8/5/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.22	65.55	8.74	N/A	2.36%	10.64%	5.14%	7/30/2025 (Estimated)

Latest SMMT, MRK, GSK, and TAK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	SMMT Summit Therapeutics	-$0.10	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	GSK GSK	$1.12	N/A	N/A	N/A	$7.92 billion	N/A
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	N/A	N/A	N/A	$7.96 billion	N/A
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	N/A	N/A	N/A	$15.92 billion	N/A
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
4/30/2025	Q1 2025	GSK GSK	$1.08	$1.13	+$0.05	$1.00	$7.52 billion	$10.06 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GSK GSK	$1.70	4.69%	N/A	87.63%	N/A
MRK Merck & Co., Inc.	$3.24	4.05%	N/A	47.16%	14 Years
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.55	3.81%	N/A	250.00%	N/A

Latest SMMT, MRK, GSK, and TAK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	GSK GSK	quarterly	$0.4216	4.1%	5/16/2025	5/16/2025	7/10/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GSK GSK	1.21	0.87	0.58
MRK Merck & Co., Inc.	0.69	1.41	1.16
SMMT Summit Therapeutics	N/A	10.63	10.63
TAK Takeda Pharmaceutical	0.57	1.01	0.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GSK GSK	15.74%
MRK Merck & Co., Inc.	76.07%
SMMT Summit Therapeutics	4.61%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
GSK GSK	10.00%
MRK Merck & Co., Inc.	0.13%
SMMT Summit Therapeutics	84.90%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GSK GSK	68,629	2.05 billion	1.84 billion	Optionable
MRK Merck & Co., Inc.	75,000	2.51 billion	2.51 billion	Optionable
SMMT Summit Therapeutics	110	742.67 million	112.14 million	Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable

SMMT, MRK, GSK, and TAK Headlines

Recent News About These Companies

Envestnet Asset Management Inc. Has $13.25 Million Holdings in Takeda Pharmaceutical Co. (NYSE:TAK)

3 hours ago | marketbeat.com

IDSA Updates Guidelines on Complicated UTIs

July 18 at 7:43 PM | medscape.comM

Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector

July 17 at 12:03 PM | seekingalpha.com

Buy Rating for Takeda Pharmaceutical Driven by Successful Phase 3 Trials of Oveporexton

July 15, 2025 | tipranks.com

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in ...

July 14, 2025 | gurufocus.com

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

July 14, 2025 | businesswire.com

Takeda: Positives And Negatives Offset Each Other

July 11, 2025 | seekingalpha.com

Vontobel Holding Ltd. Acquires New Shares in Takeda Pharmaceutical Co. (NYSE:TAK)

July 9, 2025 | marketbeat.com

Crossmark Global Holdings Inc. Purchases 186,349 Shares of Takeda Pharmaceutical Co. (NYSE:TAK)

July 8, 2025 | marketbeat.com

Callan Capital LLC Invests $735,000 in Takeda Pharmaceutical Co. (NYSE:TAK)

July 8, 2025 | marketbeat.com

Takeda Completes Treasury Share Disposal with Minor Adjustments

July 8, 2025 | tipranks.com

Lupin gets USFDA approval for post-eye surgery drug

July 2, 2025 | indiainfoline.comI

Takeda Pharmaceutical Co. (NYSE:TAK) Stock Position Raised by Sequoia Financial Advisors LLC

July 1, 2025 | marketbeat.com

FDA Approves Takeda’s Gammagard Liquid ERC

June 30, 2025 | contractpharma.comC

Takeda Pharmaceutical (NYSE:TAK) Reaches New 12-Month High - What's Next?

June 30, 2025 | marketbeat.com

Sclerosing Mesenteritis: What GIs Need to Know About This Rare Disease

June 28, 2025 | medscape.comM

Herbosa cites Dengvaxia lesson as PH mulls approval of Qdenga vaccine

June 28, 2025 | gmanetwork.comG

Sun Pharma appoints Richard Ascroft as North American CEO

June 27, 2025 | emjreviews.comE

Lupin gets U.S. FDA nod for generic of Takeda’s constipation drug

June 25, 2025 | thehindu.com

Sun Pharma Announces Appointment of Richard Ascroft as CEO North America

June 25, 2025 | finance.yahoo.com

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?

June 25, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Super Micro Stock May Benefit as Cooling Demand Takes Off
By Gabriel Osorio-Mazilli | July 16, 2025
View Super Micro Stock May Benefit as Cooling Demand Takes Off

SMMT, MRK, GSK, and TAK Company Descriptions

GSK NYSE:GSK

$36.28 -0.19 (-0.52%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$36.40 +0.13 (+0.34%)

As of 07/18/2025 07:59 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Merck & Co., Inc. NYSE:MRK

$79.97 -1.55 (-1.90%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$80.11 +0.14 (+0.17%)

As of 07/18/2025 07:59 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Summit Therapeutics NASDAQ:SMMT

$26.20 -1.43 (-5.18%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$26.36 +0.16 (+0.60%)

As of 07/18/2025 07:58 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Takeda Pharmaceutical NYSE:TAK

$14.42 -0.32 (-2.17%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$14.42 +0.01 (+0.03%)

As of 07/18/2025 04:53 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time